Navigation Links
Congress Sets New Course for Lung Cancer Research; Approves $20 Million for New Defense Department Program
Date:9/27/2008

WASHINGTON, Sept. 27 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) announced today that Congress approved $20 million for a new lung cancer research program at the Department of Defense (DOD) -- a top LCA priority.

The president is expected to sign the bill containing the new lung cancer research program and the funding will be available in fiscal year 2009 which begins October 1.

"This is our top priority; this is the turning point. It is a breakthrough that lung cancer patients, their families and caregivers have been waiting for," said Laurie Fenton-Ambrose, LCA President & CEO. "By setting up this new program, Congress is finally acknowledging that the situation is urgent and that more research must be focused on lung cancer which is causing more deaths each year than breast, prostate and colon cancers combined."

Over 215,000 people will be diagnosed with lung cancer in the United States in 2008 and the majority will die in less than a year.

The new program, entitled the Peer Reviewed Lung Cancer Research Program, will be administered and funded by the DOD.

Former Transportation Secretary Norman Y. Mineta, a member of the LCA Board of Directors and a lung cancer survivor, said that DOD is "mission-oriented" and that the department's vast experience with cutting edge technology will accelerate improvements in the detection, diagnosis and treatment of lung cancer.

Congress started funding cancer research programs through DOD in the mid-nineties with a $25 million appropriation for breast cancer. Over the years a number of research programs have been added for other cancers, but not lung cancer -- until this breakthrough.

Fenton-Ambrose praised Congressman John P. Murtha (D-PA) and Senator Daniel K. Inouye (D-HI) for their leadership and commitment on the issue.

The legislation specifically notes that lung cancer is the most lethal of all cancers, taking more lives each year than all other major cancers combined, and that military personnel have heightened exposure to lung cancer carcinogens.

"Priority shall be given to the development of the integrated components to identify, treat and manage early curable lung cancer," it states.

The bill requires the Army to provide a plan for how the $20 million will be spent and submit that plan to Congress within 120 days after the President signs the bill.

"We are also deeply indebted to our late Chairman of the Board Admiral Philip J. Coady who made this his last mission before his death in June," said Fenton-Ambrose. "We commit to his memory and to the memory of the many patient advocates who have died in the course of this effort that we will be vigilant in watching this program, and making sure that every dollar is spent wisely and effectively."

Lung Cancer Alliance (http://www.LungCancerAlliance.org) is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer. Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Media Contact:

Sheila Ross

sross@lungcanceralliance.org

202-253-6664


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Updated MD-CARE Act Receives Final Congressional Approval
2. AVMA Addresses Livestock Health Issues Before U.S. Congress
3. Lilly to Sponsor Congressional Black Caucus Foundations Annual Legislative Conference
4. ADA Asks Congress to Strengthen Medicaid Oral Health Programs
5. Pro-Life Chair to Congress: We Cant Reduce Abortions By Promoting Abortion
6. Testifying Before Congress, Trust for Americas Health Urges FDA Spending Cap Until Realistic Budget Request is Made
7. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
8. Statement From the Office of Congresswoman Stephanie Tubbs Jones
9. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
10. 1st World Congress On Interventional Therapies for Type 2 Diabetes
11. Pelosi Statement on Congress Sending Consumer Product Safety Legislation to President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: